PGT-A in IVF can inform embryo selection, but its value depends on the patient and the outcome being measured. A chromosome-screening result is not a guarantee of a healthy baby. Cumulative live birth, miscarriage, time and available embryos deserve separate attention.
Imagine a consultation in which a PGT-A result is summarized as “normal” or “abnormal.” Those shorthand labels can carry enormous weight. What the biopsy measured, and what it cannot establish, should remain visible in the discussion.
PGT-A aims to inform embryo selection. It is not a mandatory step for every IVF patient, and routine use for everyone has not demonstrated a universal benefit.
Cumulative live birth, miscarriage and time to pregnancy are distinct outcomes. Findings differ with the population and study design; an improved per-transfer result does not automatically mean more babies per retrieval.
The PGT-A Debate: An Exact Science?
PGT-A typically samples trophectoderm cells rather than the entire embryo. A mosaic-range result may reflect several biological or technical explanations. Healthy births after selected mosaic-result transfers do not establish that all abnormal-result embryos have equivalent potential.
The results appear definitive—labeled as “normal,” “abnormal,” or “mosaic” in neat tables and graphs. To patients, it feels like an objective, scientific verdict. In reality, however, the test is a matter of probability, not an absolute truth. When these tests are treated as a final, absolute standard, a dangerous gap widens.
The clinical landscape is slowly shifting. While mosaic embryos were once treated as “to be discarded,” we are now seeing an emergence of conditional transfer attempts. Some guidelines now advise against the routine use of PGT-A for all patients, recommending a more selective approach. This is not merely a technical debate; it is a sign that our very approach to life itself is being re-evaluated.
Counseling should ask which outcome the patient hopes to improve, how many embryos are available and what the evidence suggests in their situation. Neither fewer failures nor a shorter journey is guaranteed.
The editorial concern is the placement of the test: a useful tool can become misleading when presented as an infallible verdict. Patients deserve an explanation of both potential benefits and limitations.
Ultimately, one question remains: Are we truly selecting better embryos, or are we erasing too many possibilities? The essence of IVF remains unchanged: it is not about evaluating embryos, but about creating the conditions in which life can thrive. And today, we are once again returning to that most fundamental of all questions.
Disclaimer: This content is provided for informational purposes, based on reporting on infertility and various public data. Medical judgments and treatment decisions must always be made in consultation with professional medical personnel. Image: AI-generated (ChatGPT, OpenAI) / Visual reference for illustrative purposes only.
What chromosome screening can establish
Routine PGT-A has not demonstrated universal benefit for every IVF patient. The testing indication and outcome of interest matter. ASRM: PGT-A committee opinion (2024).
Related reading
Mosaic Embryo Transfer: How Do You Choose When the Answer Is Uncertain?